Pharmaceutical

Filter

Current filters:

None

Popular Filters

53 to 77 of 7004 results

Merck & Co’s melanoma drug Keytruda becomes first FDA-approved anti-PD-1 therapy

Merck & Co’s melanoma drug Keytruda becomes first FDA-approved anti-PD-1 therapy

05-09-2014

The US Food and Drug Administration has granted accelerated approval for pharma giant Merck & Co’s…

KeytrudaMerck & CoOncologypembrolizumabPharmaceuticalRegulationUSA

IQWiG finds no added benefit for Astellas’ Betmiga

IQWiG finds no added benefit for Astellas’ Betmiga

04-09-2014

Japanese drug major Astellas Pharma's Betmiga (mirabegron), which has been approved in Germany since…

Astellas PharmaBetmigaGenito-urinaryGermanyPharmaceutical

Redx Pharma and AstraZeneca collaborate on oncology research

04-09-2014

UK-based drug discovery firm Redx Pharma says it has entered into a research collaboration with Anglo-Swedish…

AstraZenecaOncologyPharmaceuticalRedx PharmaResearch

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

04-09-2014

US pharma major Eli Lilly has released additional clinical data showing superiority for its diabetes…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

United Arab Emirates’ health care market among strongest in Middle East

04-09-2014

The United Arab Emirates (UAE) is second only to Saudi Arabia in terms of pharmaceutical investment in…

HealthcareMarkets & MarketingPharmaceuticalRest of the World

High long-term efficacy of LEO Pharma’s Picato in actinic keratosis confirmed

04-09-2014

New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers…

DermatologicalsLEO PharmaPharmaceuticalPicatoResearch

Sepsis-specific therapies are desperately needed but hard to develop, says GlobalData

Sepsis-specific therapies are desperately needed but hard to develop, says GlobalData

04-09-2014

There is an urgent need to develop sepsis-specific therapies, according to research by consulting firm…

Antibiotics and Infectious diseasesGlobalDataPharmaceuticalResearchSepsis

Infinity and AbbVie collaborate on duvelisib in deal worth up to $805 million

Infinity and AbbVie collaborate on duvelisib in deal worth up to $805 million

03-09-2014

US drug discovery firm Infinity Pharmaceuticals has entered into a global collaboration with AbbVie to…

AbbVieduvelisibInfinity PharmaceuticalsIPI-145LicensingOncologyPharmaceutical

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

03-09-2014

The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq (dolutegravir…

Anti-viralsEuropeGlaxoSmithKlinePharmaceuticalRegulationTriumeqViiV Healthcare

Luye Pharma to acquire majority stake in Beijing Jialin for $599 million

Luye Pharma to acquire majority stake in Beijing Jialin for $599 million

03-09-2014

Hong Kong-based Luye Pharma has entered into an agreement to purchase a 57.98% stake of Beijing Jialin…

Beijing Jialin PharmaceuticalCardio-vascularChinaLuye PharmaMergers & AcquisitionsPharmaceutical

FDA accepts Actavis NDA for eluxadoline

FDA accepts Actavis NDA for eluxadoline

03-09-2014

Ireland-headquartered generic drug major Actavis says that the US Food and Drug Administration has accepted…

ActaviseluxadolineForest LaboratoriesFuriex PharmaceuticalsGastro-intestinalsPharmaceuticalRegulationUSA

Bristol-Myers Squibb launches Daklinza in the UK for chronic hepatitis C

Bristol-Myers Squibb launches Daklinza in the UK for chronic hepatitis C

03-09-2014

US drug major Bristol-Myers Squibb has launched Daklinza (daclastavir) in the UK for chronic hepatitis…

AntiviralsBristol-Myers SquibbDaklinzaHepatitis CNephrology and HepatologyPharmaceuticalRegulationUK

Lundbeck launches Northera in USA

Lundbeck launches Northera in USA

02-09-2014

Danish CNS specialist Lundbeck said today that Northera (droxidopa) capsules for oral use are now available…

Chelsea TherapeuticsLundbeckMarkets & MarketingNeurologicalNortheraPharmaceuticalUSA

Allergan’s Ozurdex approved for DME in Europe

Allergan’s Ozurdex approved for DME in Europe

02-09-2014

Allergan revealed today that the European Commission has extended the marketing authorization for Ozurdex…

AllerganEuropeOphthalmicsOzurdexPharmaceuticalRegulation

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

02-09-2014

German pharma and chemical major Bayer has released results from the X-VeRT* study, demonstrating that…

BayerCardio-vascularPharmaceuticalResearchXarelto

Novo Nordisk pulls out of inflammatory disorders research

Novo Nordisk pulls out of inflammatory disorders research

02-09-2014

Danish diabetes care giant Novo Nordisk says it has decided to discontinue all its R&D activities within…

Anti-Arthritics/RheumaticsInflammatory diseasesNovo NordiskPharmaceutical

New EMA guidance on EU periodic-safety-update-report single assessment for nationally authorized medicines

01-09-2014

The European Medicines Agency has updated its procedural guidance to ensure that marketing-authorization…

EuropePharmaceuticalRegulation

53 to 77 of 7004 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top